Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 7, 2010, Pages 1505-1509

  Nelson, Mark ^a   Girard, Pierre Marie ^b,c,d   DeMasi, Ralph ^e   Chen, Liddy ^e   Smets, Erik ^f   Sekar, Vanitha ^e   Lavreys, Ludo ^g  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b HÔPITAL SAINT ANTOINE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSERM   (France)

^e Tibotec   (United States)

^f JOHNSON AND JOHNSON   (United States)

^g TIBOTEC BVBA   (Belgium)

Author keywords

Phase III; Protease inhibitors; TMC114; Treatment compliance

Indexed keywords

DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DARUNAVIR; LOPINAVIR; PYRIMIDINONE DERIVATIVE; RITONAVIR; SULFONAMIDE;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ETHNIC DIFFERENCE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; SELF REPORT; TREATMENT DURATION; TREATMENT RESPONSE; ADULT; CONTROLLED STUDY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MEDICATION COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; LOPINAVIR; MEDICATION ADHERENCE; PYRIMIDINONES; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77954183998     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq150     Document Type: Article

References (11)

1. Ortiz R, DeJesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1- infected patients at 48 weeks. AIDS 2008; 22: 1389-97.
2. Mills AM, Nelson M, Jayaweera D et al. Once-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-naïve, HIV-1-infected patients: 96-week analysis of ARTEMIS. AIDS 2009; 23: 1679-88.
3. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.December 1, 2009. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (1 December 2009, date last accessed).
4. Murri R, Cingolani A, De Luca A et al. Once-daily regimens were associated with a higher rate of self-chosen discontinuations. HIV Med 2009; 10 Suppl 2: 146-7. Abstract PE10.1/7.
5. Mills TM, Chetchotisakd P, DeMasi R et al. Adherence to darunavir/ritonavir (DRV/r) and lopinavir/r (LPV/r) in treatment-naïve patients in ARTEMIS. Global Antivir J 2008; 4 Suppl 1: 67. Abstract 61.
6. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 2002; 16: 269-77.
7. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
8. Shuter J, Sarlo JA, Kanmaz TJ et al. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates ,95%. J Acquir Immune Defic Syndr 2007; 45:4-8.
9. Martin M, Del Cacho E, Codina C et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses 2008; 24: 1263-8.
10. Shuter J, Sarlo JA, Rode RA et al. Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy. HIV Clin Trials 2009; 10: 135-42.
11. Dierynck I, De Wit M, Gustin E et al. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol 2007; 81: 13845-51.